<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bremelanotide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bremelanotide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bremelanotide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="121792" href="/d/html/121792.html" rel="external">see "Bremelanotide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53506765"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vyleesi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53317769"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Melanocortin Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F53415537"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Discontinue use of bremelanotide if no improvement in symptoms after 8 weeks.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="197ee9e7-821a-4e63-8d16-54c1fd1165d7">Hypoactive sexual desire disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoactive sexual desire disorder:</b> SUBQ: 1.75 mg as needed, ≥45 minutes before sexual activity (maximum: 1.75 mg/24 hours). No more than 8 doses per month are recommended.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F53415539"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use with caution.</p></div>
<div class="block doha drugH1Div" id="F53415540"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A and B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use with caution (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F53415538"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F53328326"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin hyperpigmentation (1% to 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (3%), paresthesia (3%), dizziness (2%), pain (&lt;2%), restless leg syndrome (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (5%), diarrhea (&lt;2%), upper abdominal pain (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), increased creatine phosphokinase in blood specimen (&lt;2%), limb pain (&lt;2%), myalgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (3%), nasal congestion (2%), rhinorrhea (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased heart rate</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Hypoesthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Injection site pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms</p></div>
<div class="block coi drugH1Div" id="F53317614"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Uncontrolled hypertension or known cardiovascular disease</p></div>
<div class="block war drugH1Div" id="F53415522"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular: A transient increase in blood pressure and reduction in heart rate may occur after each dose; peak effects occur 2 to 4 hours post-dose and typically return to baseline within 12 hours. Use is not recommended in patients at high risk for cardiovascular disease and is contraindicated in patients with uncontrolled hypertension or established cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Focal hyperpigmentation: Focal hyperpigmentation, including involvement of the face, gingiva, and breasts, has been reported. May occur more frequently in patients with dark skin and with more frequent administration. Consider discontinuation if focal hyperpigmentation develops; may resolve in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal: Nausea, especially after the initial dose, has been reported. Onset usually occurs within 1 hour post-dose and may last approximately 2 hours. Incidence commonly decreases with subsequent doses. Use of an antiemetic may be effective; discontinuation of therapy may be considered for persistent or severe nausea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues</b></i>
<i>
<b>:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed gastric emptying: May delay gastric emptying and reduce the rate and extent of absorption of concurrently administered oral drugs. Monitor for efficacy of concurrently administered oral drugs and consider discontinuation of bremelanotide if efficacy is affected. Additionally, concurrent use with oral drugs dependent on threshold concentrations for efficacy (eg, antibiotics) may need to be avoided.</p></div>
<div class="block foc drugH1Div" id="F53506766"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyleesi: 1.75 mg/0.3 mL (0.3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Auto-injector, Subcutaneous, as acetate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyleesi: 1.75 mg/0.3 mL (0.3 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F53496744"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53559999"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Auto-injector</b> (Vyleesi Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.75 mg/0.3 mL (per 0.3 mL): $269.70</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F53415541"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">SubQ: Administer SubQ in the abdomen or thigh.</p></div>
<div class="block use drugH1Div" id="F53317613"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoactive sexual desire disorder:</b> Treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is <b>not</b> due to a coexisting medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not indicated for the treatment of HSDD in postmenopausal women or in men or to enhance sexual performance.</p></div>
<div class="block cyt drugH1Div" id="F53350231"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53350228"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Indomethacin: Bremelanotide may decrease the serum concentration of Indomethacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone: Bremelanotide may decrease the serum concentration of Naltrexone. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53415520"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients who may become pregnant should use effective contraception during bremelanotide therapy.</p></div>
<div class="block pri drugH1Div" id="F53415519"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome information following maternal use of bremelanotide during pregnancy is limited. Discontinue if pregnancy is suspected.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to bremelanotide is ongoing. Health care providers are encouraged to enroll females exposed to bremelanotide during pregnancy in the Vyleesi Pregnancy Registry (800-972-5220).</p></div>
<div class="block brc drugH1Div" id="F53415521"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bremelanotide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F53415543"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure and heart rate (if clinically indicated)</p></div>
<div class="block pha drugH1Div" id="F53415525"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nonselective melanocortin receptor agonist that activates several receptor subtypes, most notably MC4R (present throughout the CNS) and MC1R (expressed on melanocytes). Mechanism for improvement of hypoactive sexual desire disorder is unknown.</p></div>
<div class="block phk drugH1Div" id="F53415526"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 25 ± 5.8 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 21%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily amide hydrolysis of the cyclic peptide</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~100%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, terminal: ~2.7 hours (range: 1.9 to 4 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (64.8%); feces (22.8%)</p></div>
<div class="block phksp drugH1Div" id="F53415534"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with mild (eGFR 60 to 89 mL/minute/1.73 m<sup>2</sup>), moderate (eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>), and severe (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>) renal impairment, AUC increased by 1.2-, 1.5-, and 2-fold, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment, AUC increased by 1.2- and 1.7-fold, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58215742"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vyleesi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Vyleesi (bremelanotide) [prescribing information]. Cranbury, NJ; Palatin Technologies, Inc; February 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 121712 Version 44.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
